1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Roche Touts Safety Profile For NMOSD Drug Satralizumab

Approvals Sought For Rare Disorder

 
• By Kevin Grogan

With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.

Blue man
Rare: NMOSD affects 10,000 people in Europe, • Source: Shutterstock

With regulatory decisions approaching for satralizumab, Roche has presented long-term data which the company claims reinforce the safety of its investigational neuromyelitis optica spectrum disorder (NMOSD) drug.

The Swiss major has presented pooled safety results at the European Academy of Neurology (EAN) meeting from the SAkuraStar and SAkuraSky Phase III studies which showed that the rates of adverse events were comparable between satralizumab and placebo groups as a monotherapy or in combination with baseline therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.